Funds will help advance MDS Education, Advocacy
and Research
SAN
DIEGO, Dec. 11, 2023 /PRNewswire/ -- Notable
Labs, ("Notable") (Nasdaq: NTBL), a clinical stage therapeutic
platform company developing predictive precision medicines for
cancer patients, today announced that it has donated
$60,000 to the Myelodysplastic
Syndrome Foundation, Inc. This donation was formally announced
during the MDS Foundation 2023 Satellite Symposium at the 65th
American Society of Hematology (ASH) Annual Meeting which Notable
Labs also supported here in San Diego,
Ca.
"This funding illustrates our strong commitment to researching
and developing precision treatments for MDS – a cancer with
extremely high unmet need," said Thomas
Bock, MD, CEO, Notable Labs. "Supporting the MDS
Foundation directly aligns with our desire to affect positive
change not only for patients, but also the researchers who work to
find cures for this incapacitating disease."
Notable Labs served as a National Gold Sponsor of the 2023 "Move
for MDS Community Walks to Drive Awareness & Accelerate
Research." These events occurred in Chicago, New York
City, Los Angeles,
Nashville, and Boston. There is also a virtual event that
remains ongoing for anyone interested in participating at any
time. We encourage everyone to participate or donate
here.
"We are extremely grateful to Notable Labs for their generous
sponsorship of our 2023 Move for MDS walks," said Tracey Iraca, Executive Director, MDS
Foundation. "The funds raised by the MDS Foundation are used
to educate patients and caregivers, as well as to raise awareness
of MDS in the community. We also work tirelessly to educate
healthcare providers and support innovative research in the fields
of MDS and its related continuum of diseases to better diagnose,
control and ultimately cure these diseases."
For more information about Move for MDS, please visit:
https://moveformds.org/#about-mds.
About Notable Labs
Notable Labs, Ltd. is a clinical-stage platform therapeutics
company developing predictive precision medicines for patients with
cancer. Through its proprietary Predictive Precision Medicines
Platform (PPMP), Notable Labs bio-simulates a cancer treatment and
aims to predict whether or not a patient is likely to respond to
that specific therapeutic. Notable Labs' PPMP is designed to
identify and select clinically responsive patients prior to their
treatment and thus fast-track clinical development in this patient
population. By continually advancing and expanding the reach of the
PPMP across diseases and predicted medical outcomes, Notable Labs
aims to be the leader in precision medicine and revolutionize the
way in which patients seek and receive treatments that work best
for them – patient by patient and cancer by cancer. Notable Labs
believes it has created a targeted and de-risked in-licensing
strategy to deliver a product's medical impact and commercial value
faster, higher, and with a greater likelihood of success than
traditional drug development. By transforming historical standards
of care, Notable Labs aims to create dramatic positive impact for
patients and the healthcare community. Notable Labs is
headquartered in Foster City,
California. Learn more at www.NotableLabs.com and follow us
@NotableLabs.
About the MDS Foundation, Inc.
The MDS Foundation has been at the forefront of providing
comprehensive support and education for the MDS community for
nearly 30 years. With a vision to ensure that every MDS patient
benefits from early initiatives and research, the foundation
focuses on better diagnosis, control, and ultimately, the cure of
MDS and its related diseases. As part of their ongoing commitment
to the MDS patient population, the foundation has initiated a
project to raise awareness about clinical trials, streamline the
search process, and facilitate patient-care team interactions. For
more information and to access the new portal, visit
www.mds-foundation.org.
Media contacts:
John F. Kouten
JFK Communications, Inc.
908-227-4714
jfkouten@jfkhealth.com
Tracey Iraca, Executive
Director
MDS Foundation, Inc.
tiraca@mds-foundation.org
609-298-1600 x211
View original content to download
multimedia:https://www.prnewswire.com/news-releases/notable-labs-funds-myelodysplastic-syndromes-foundation-with-60-000-grant-302010960.html
SOURCE Notable Labs